 | | Vol. 8.48 – 8 December, 2020 |
| |
|
|
| Scientists confirmed the immunogenicity of frameshift peptides in T cell stimulation experiments using blood mononuclear cells isolated from both healthy donors and microsatellite instability-high cancer patients.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To identify the global regulatory networks controlling antigen presentation, researchers employed genome-wide screening in human diffuse large B cell lymphomas.
[Immunity] |
|
|
|
| Scientists provided a protocol for the synthesis of the amphiphilic dendrimer, as well as siRNA delivery to immune cells such as primary T and B cells, natural killer cells, macrophages, and primary microglia.
[Nature Protocols] |
|
|
|
| Investigators obtained a detailed immune cell atlas of esophageal squamous cell carcinoma at single-cell resolution. Exhausted T and NK cells, regulatory T cells, alternatively activated macrophages and tolerogenic dendritic cells were dominant in the tumor microenvironment.
[Nature Communications] |
|
|
|
| To generate spatially-resolved tumor and immune cell data at single cell resolution, the authors developed two quantitative multiplex immunofluorescence assays to interrogate myeloid cells and macrophages in the pancreatic ductal carcinoma tumor microenvironment.
[Clinical Cancer Research] |
|
|
|
| Human mRNA transcript profiling at multiple time points permited the tracking of the reprogramming of B cell nuclei to a multipotent state. Interrogation of a human B cell regulatory network with gene expression signatures identified eight candidate master regulator proteins.
[Cell Reports] |
|
|
|
| Scientists present three patients with aggressive non-Hodgkin’s B-cell lymphoma who received anti-CD19 chimeric antigen receptor T cells therapy after failure of several lines of chemotherapy that developed pseudo-progression.
[Bone Marrow Transplantation] |
|
|
|
| Investigators selectively activated and expanded stem-cell donor-derived T cells that were reactive to multiple antigens expressed by acute myeloid leukemia/myelodysplastic syndrome cells
[Blood] |
|
|
|
| Functional studies with gene-overexpressed and gene-silenced DLBCL cell lines showed that expression of NANOG and HOXA9 promoted cell viability and inhibited apoptosis through suppression of G2 arrest in vitro and enhanced tumor formation and hepatosplenic infiltration in a tail-vein-injected mouse model.
[Scientific Reports] |
|
|
|
| Researchers treated peripheral blood mononuclear cells of healthy adults with the biologically active form of vitamin D3, 1α,25-dihydroxyvitamin D3 using two different approaches and personalized analysis based on triplicates of five study participants.
[Scientific Reports] |
|
|
|
|
| Allergic rhinitis (AR) is caused by immunoglobulin E-mediated reactions to inhaled allergens and is one of the most common chronic conditions globally. AR often co-occurs with asthma and conjunctivitis and is a global health problem causing major burden and disability worldwide.
[Nature Reviews Disease Primers] |
|
|
|
| Scientists provide a wide perspective on the regulatory mechanisms, including crosstalk with other cell types, downstream signaling pathways, transcription factors, and epigenetics, underlying the acquisition of tolerogenesis by dendritic cells, with a special focus on human studies.
[Trends in Immunology] |
|
|
|
| By reviewing the different biological and molecular aspects of neuroblastoma and anti-GD2 antibodies (GD2-IMT), the author questions the present lack of association between GD2-IMT and the underlying molecular landscape.
[Cancer Letters] |
|
|
|
|
| Turnstone Biologics Corp., have enrolled the first patients in a Phase I/IIa clinical trial of its RIVAL-01/TAK-605 candidate in patients with solid tumors, conducted in collaboration with Takeda Pharmaceutical Company Limited. RIVAL-01 consists of Turnstone’s proprietary oncolytic vaccinia virus backbone encoding transgenes for Flt3 ligand, anti-CTLA-4 antibody and IL-12 cytokine, purposefully designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication.
[Turnstone Biologics Corp. (Businesswire, Inc.)] |
|
|
|
| The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application to the FDA seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
[Janssen, LLC] |
|
|
|
|
| January 19 – January 21, 2021
Virtual |
|
|
|
|
|
| | Salk Institute of Biological Studies – La Jolla, California, United States |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | University of California Irvine – Irvine, California, United States |
|
|
|
| | Queen’s University – Kingston, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
